Hologic, Inc. to Post Q3 2025 Earnings of $1.12 Per Share, Zacks Research Forecasts (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Zacks Research upped their Q3 2025 earnings per share estimates for Hologic in a report issued on Wednesday, September 4th. Zacks Research analyst M. Mondal now anticipates that the medical equipment provider will post earnings of $1.12 per share for the quarter, up from their prior estimate of $1.11. The consensus estimate for Hologic’s current full-year earnings is $4.09 per share. Zacks Research also issued estimates for Hologic’s FY2025 earnings at $4.37 EPS.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. Hologic’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.93 EPS.

Several other brokerages have also recently issued reports on HOLX. JPMorgan Chase & Co. boosted their price target on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Argus upped their price target on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Stephens reaffirmed an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Evercore ISI boosted their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. Finally, StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 10th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $80.99 on Friday. Hologic has a one year low of $64.02 and a one year high of $84.67. The stock has a market capitalization of $18.90 billion, a price-to-earnings ratio of 41.32, a PEG ratio of 2.57 and a beta of 0.99. The company has a 50-day simple moving average of $79.30 and a 200-day simple moving average of $76.57. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Institutional Investors Weigh In On Hologic

Large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its position in Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the last quarter. Norges Bank acquired a new position in shares of Hologic during the 4th quarter worth approximately $217,529,000. The Manufacturers Life Insurance Company lifted its stake in Hologic by 21.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after buying an additional 450,190 shares in the last quarter. Black Creek Investment Management Inc. grew its holdings in Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after buying an additional 885,524 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Hologic by 5.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock worth $172,780,000 after buying an additional 124,739 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now directly owns 45,472 shares in the company, valued at $3,615,024. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The disclosure for this sale can be found here. Insiders sold 18,280 shares of company stock worth $1,469,973 over the last 90 days. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.